Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Study of Nizubaglustat in GM2 Gangliosidosis or Niemann-Pick Type C Disease
NCT07399704Phase 2Active, not recruiting
- Sponsor
- Azafaros
- Start
- Feb 2026
- Primary completion
- Jun 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nizubaglustat in GM2 gangliosidosis, Niemann-Pick disease type C (NPC), sponsored by Azafaros. Started Feb 2026; status: active, not recruiting.
02
Drugs
nizubaglustat
03
Conditions
GM2 gangliosidosisNiemann-Pick disease type C (NPC)
Beyond the preview
Go deeper on NCT07399704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07399704.